Pinaverium

# Pinaverium ## Overview - **Classification**: Selective gastrointestinal calcium channel blocker, antispasmodic - **Mechanism**: Blocks L-type voltage-dependent calcium channels in intestinal smooth muscle cells, reducing muscle contraction and spasms. ## Primary Indications 1. **Irritable Bowel Syndrome (IBS)** - Symptomatic treatment of pain, discomfort, and transit disturbances. ## Adult Dosing ### Standard Dosing **Irritable Bowel Syndrome (IBS)** - **Dose**: **50 mg** or **100 mg** - **Frequency**: Three times daily (TID) - **Route**: Oral - **Duration**: As needed for symptoms; typically long-term for chronic conditions. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustments provided; use with caution. - **Hepatic Impairment**: No specific dose adjustments provided; use with caution. - **Elderly Patients**: No specific dose adjustments required; use adult dosing. ## Pediatric Dosing **Note**: Pinaverium is generally **not recommended for patients under 18 years** due to insufficient data on efficacy and safety in these age groups. ### Neonates (0-28 days) - **Dose**: Not recommended. - **Special Notes**: Use is contraindicated due to lack of safety and efficacy data. ### Infants (1-12 months) - **Dose**: Not recommended. - **Special Notes**: Use is contraindicated due to lack of safety and efficacy data. ### Children (1-12 years) - **Dose**: Not recommended. - **Special Notes**: Use is contraindicated due to lack of safety and efficacy data. ### Adolescents (13-18 years) - **Dose**: Not recommended due to insufficient data. - **Maximum**: Not applicable as use is not recommended. - **Special Notes**: Safety and efficacy have not been established. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to pinaverium or any excipients. - **Absolute**: Esophageal lesions or conditions predisposing to esophageal injury (e.g., hiatus hernia, previous esophageal trauma). - **Absolute**: Generally not recommended for pediatric patients under **18 years**. ### Common Adverse Effects - **Common (1-10%)**: Abdominal pain, dysphagia (difficulty swallowing), nausea, rash, pruritus. - **Serious but Rare**: Esophageal injury (e.g., ulceration) if not taken correctly. ### Key Drug Interactions - No clinically significant drug-drug interactions are well-established for pinaverium. - **Antacids**: May reduce pinaverium absorption. Separate administration by at least **2 hours**. ## Monitoring & Follow-up - **Before Treatment**: Assess for pre-existing esophageal conditions. - **During Treatment**: Monitor for symptom improvement and gastrointestinal adverse effects (e.g., dysphagia, heartburn). - **Clinical Signs**: Watch for persistent or worsening GI symptoms, especially signs of esophageal irritation. ## Clinical Pearls - 💡 **Timing**: Always take **before meals** (e.g., 15-20 minutes prior) to minimize esophageal irritation. - 💡 **Administration**: Swallow tablets **whole** with a full glass of water. Do not chew or crush. - 💡 **Counseling**: Emphasize proper administration technique to prevent esophageal adverse effects. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.